ASCO 2022: Data for Better Decision-Making in the Treatment of Advanced Bladder Cancer

Tracy L. Rose, MD, MPH

June 27, 2022

Tracy L. Rose, MD, MPH, shares the immediate and direct impact of the long-term follow-up data from the JAVELIN Bladder 100 trial, an avelumab maintenance study in patients with advanced urothelial carcinoma, which was part of a poster session at the 2022 ASCO annual meeting. The results of the 38-month follow-up data showed prolonged overall survival in patients using first-line avelumab maintenance along with best supportive care who had not progressed during initial induction treatment with platinum-based chemotherapy.

Dr Rose also reviews survey results presented by Dr Shilpa Gupta that looked to define parameters on which patients would be considered "platinum-ineligible." These new consensus definitions will help guide first-line treatment decisions.

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Cite this: ASCO 2022: Data for Better Decision-Making in the Treatment of Advanced Bladder Cancer - Medscape - Jun 27, 2022.

Comments

Commenting is limited to medical professionals. To comment please Log-in.

Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.